Skip to main content

Advertisement

Table 3 Bivariate and multivariable analysis for progression-free survival

From: Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer

Characteristic Crude HR (95% CI) P-value* (bivariatea) Adjusted HR (95% CI) P-value* (multivariablea)
Primary tumor location
 Right vs. Left 2.09 (1.31–3.33) 0.002 1.55 (0.92–2.61) 0.099
Age
 >60 years vs. ≤ 60 0.77 (0.54–1.08) 0.133 0.77 (0.53–1.13) 0.180
Gender
 Female vs. Male 1.15 (0.80–1.64) 0.449 1.11 (0.75–1.64) 0.616
Stage at presentation
 Stage IV vs. Stage I-III 0.99 (0.66–1.49) 0.965   
Histologic grade
 P/D or SRC vs. W/D or M/D 5.37(2.24–12.87) <0.001 3.06 (1.22–7.67) 0.017
Presence of liver metastasis
 Yes vs. No 1.04 (0.73–1.50) 0.816   
Presence of lung metastasis
 Yes vs. No 0.87 (0.63–1.21) 0.419   
Presence of peritoneal metastasis
 Yes vs. No 2.53 (1.53–4.19) <0.001 2.08 (1.19–3.63) 0.010
Number of metastasized organs
 ≥ 2 vs. 1 1.11 (0.80–1.53) 0.543   
BRAF
 Mutant vs. Wild-type 3.56 (2.11–6.01) <0.001 3.07 (1.73–5.46) <0.001
PIK3CA
 Mutant vs. Wild-type 2.60 (0.95–7.11) 0.062   
  1. Abbreviations: HR hazard ratio, CI confidence interval, P/D poorly differentiated, SRCC signet ring cell carcinoma, W/D well-differentiated, M/D moderately differentiated
  2. *P-value by Cox’s proportional hazards regression
  3. aClinically meaningful variables and those with p < 0.05 by bivariate analysis were entered into the multivariable analysis model